Urolithin A and heart

What 2 graded rows on urolithin a agree on for heart, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Urolithin A page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Urolithin A page, with its PubMed record.

Supplement

Urolithin A Choose another

2 rows · 60 people

They agree: both rows found no difference.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade C, is a randomized trial of 50 people (2026) and found no difference.

The rows run from 10 to 50 people, published from 2024 to 2026: 2 single studies.

2 no difference

Grade CEndothelial function (flow-mediated dilation) · No difference
RCT · n 50 · 2026 · US adults aged 40 to 64 with obesity (BMI 30 or more)
1,000 mg/day · 4 weeks
Flow-mediated dilation did not change more than with placebo (1.3% with urolithin A vs 0.3% with placebo, not significant), nor did other endothelial measures. Task-evoked brain blood-flow responses rose with urolithin A while task performance did not change. It was well tolerated.
Row on the Urolithin A page · PubMed 42853569 (opens PubMed)
Grade DHeart function (ejection fraction) and blood markers in heart failure · No difference
Crossover RCT · n 10 · 2024 · Patients in Iran with heart failure with reduced ejection fraction
500 mg twice daily · 4 weeks per period, 2-week washout
No change in echocardiographic measures, pro-BNP, glucose or CRP versus placebo; HDL cholesterol rose by 6.46 mg/dL.
Row on the Urolithin A page · PubMed 38415449 (opens PubMed)